Elevation Oncology Q4 EPS $(0.19) Beats $(0.23) Estimate; Cash, Cash Equivalents And Marketable Securities And Approximately $17M In Net Proceeds Raised Under Its ATM Facility Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
Elevation Oncology Q4 EPS $(0.19) Beats $(0.23) Estimate; Cash, Cash Equivalents And Marketable Securities And Approximately $17M In Net Proceeds Raised Under Its ATM Facility Is Expected To Provide Cash Runway Into Fourth Quarter Of 2025
Elevation Oncology第四季度每股收益美元（0.19美元）超过预期（0.23美元）；现金、现金等价物和有价证券以及通过其自动柜员机筹集的约1700万美元净收益预计将为2025年第四季度提供现金流道
Elevation Oncology (NASDAQ:ELEV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 76.83 percent increase over losses of $(0.82) per share from the same period last year.
Elevation Oncology（纳斯达克股票代码：ELEV）公布的季度亏损为每股0.19美元，比分析师共识估计的美元（0.23美元）高出17.39％。这比去年同期每股亏损0.82美元（0.82美元）增长了76.83％。